NASDAQ · JAN
Industrials · Waste Management
$30.50
Down-$0.21 (-0.68%)
Updated Aug 29, 2026, 8:05 PM
SID Score
—
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 21 trading sessions · Daily adjusted prices
JAN closed at $30.50 after 21 trading sessions, up 0.96% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 28, 2026 | $30.73 | $30.94 | $30.41 | $30.50 | 575.93K |
| Aug 27, 2026 | $31.43 | $31.83 | $30.66 | $30.71 | 1.22M |
| Aug 26, 2026 | $31.46 | $31.93 | $31.44 | $31.76 | 1.11M |
| Aug 25, 2026 | $31.17 | $31.53 | $30.94 | $31.35 | 889.04K |
| Aug 24, 2026 | $30.99 | $31.30 | $30.66 | $31.20 | 1.15M |
| Aug 21, 2026 | $30.83 | $31.005 | $30.60 | $30.71 | 815.19K |
| Aug 20, 2026 | $30.56 | $30.94 | $30.37 | $30.59 | 992.5K |
| Aug 19, 2026 | $30.76 | $30.97 | $30.32 | $30.56 | 1.23M |
| Aug 18, 2026 | $30.63 | $31.14 | $30.25 | $30.41 | 1.78M |
| Aug 17, 2026 | $30.53 | $30.53 | $30.10 | $30.41 | 1.2M |
| Aug 14, 2026 | $29.86 | $30.70 | $29.76 | $30.63 | 1.12M |
| Aug 13, 2026 | $29.48 | $30.04 | $29.20 | $29.93 | 2.06M |
| Aug 12, 2026 | $29.60 | $29.96 | $29.10 | $29.10 | 3.26M |
| Aug 11, 2026 | $29.42 | $29.75 | $28.95 | $29.57 | 8.76M |
| Aug 10, 2026 | $30.36 | $30.48 | $29.99 | $30.18 | 1.26M |
| Aug 7, 2026 | $29.98 | $30.71 | $29.825 | $30.47 | 1.97M |
| Aug 6, 2026 | $30.49 | $31.20 | $29.50 | $29.69 | 2.12M |
| Aug 5, 2026 | $31.77 | $31.77 | $30.02 | $30.49 | 3.45M |
| Aug 4, 2026 | $29.56 | $30.05 | $28.89 | $29.91 | 1.85M |
| Aug 3, 2026 | $30.17 | $30.575 | $29.49 | $29.55 | 2.23M |
| Jul 31, 2026 | $30.09 | $30.57 | $29.77 | $30.21 | 1.06M |
The latest Smart Investors Daily articles mentioning JAN.
JAN research
Company profile and research snapshot.
JanOne Inc., a clinical-stage biopharmaceutical company, focuses on identifying, acquiring, licensing, developing, partnering, and commercializing novel, non-opioid, and non-addictive therapies to address the unmet medical need for the treatment of pain and addiction. It operates through three segments: Biotechnology, Recycling, and Technology. The company's lead product candidate is JAN101, a patented oral and sustained release pharmaceutical composition of sodium nitrite that targets poor blood flow to the extremities in patients with diabetes or peripheral artery disease to treat pain. It also provides turnkey appliance recycling and replacement services for utilities and other sponsors of energy efficiency programs; and designs, develops, and sells cellular transceiver modules and associated wireless services. The company was formerly known as Appliance Recycling Centers of America, Inc. and changed its name to JanOne Inc. in September 2019. JanOne Inc. was founded in 1976 and is headquartered in Las Vegas, Nevada.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 18, 2026 | Morgan Stanley | Overweight | — |
| Aug 18, 2026 | JP Morgan | Overweight | — |
| Aug 10, 2026 | RBC Capital | Outperform | — |
| Aug 6, 2026 | Cantor Fitzgerald | Overweight | — |
| Jul 15, 2026 | Wells Fargo | Overweight | — |
No generated briefing is available yet.
proactiveinvestors.co.uk · Sep 26, 2025
Jangada Mines PLC (AIM:JAN) shares climbed in Friday's trade, after the company announced the sale of its holding in Blencowe Resources and said it would focus on its gold strategy. The company will now prioritise the Paranaíta gold project in Brazil.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning JAN.
